Remicade Rheumatoid Arthritis X-Ray Data Sealed J&J Purchase Of Centocor
Executive Summary
Interim data from Centocor's Remicade in rheumatoid arthritis, initially available to the company in mid-June, convinced Johnson & Johnson to purchase the biotechnology company.
You may also be interested in...
Centocor Remicade
Placebo arm of Phase III rheumatoid arthritis trial (ATTRACT) has been unblinded after investigators discovered greater efficacy for infliximab in one-year x-ray data. The two-year 428-patient trial will keep the four methotrexate/Remicade treatment arms blinded but methotrexate/placebo patients will be given the option to roll into an open-label trial (PROMPT) and use low-dose Remicade (3 mg/kg every eight weeks) in combination with methotrexate. The x-ray data will be presented at the American College of Rheumatology annual meeting in Boston on Nov. 15. Centocor also denied rumors that Lilly has made an offer to purchase the company (1"The Pink Sheet" Sept. 13, p. 5)
Centocor Remicade
Placebo arm of Phase III rheumatoid arthritis trial (ATTRACT) has been unblinded after investigators discovered greater efficacy for infliximab in one-year x-ray data. The two-year 428-patient trial will keep the four methotrexate/Remicade treatment arms blinded but methotrexate/placebo patients will be given the option to roll into an open-label trial (PROMPT) and use low-dose Remicade (3 mg/kg every eight weeks) in combination with methotrexate. The x-ray data will be presented at the American College of Rheumatology annual meeting in Boston on Nov. 15. Centocor also denied rumors that Lilly has made an offer to purchase the company (1"The Pink Sheet" Sept. 13, p. 5)
Centocor Remicade RA Launch Will Get J&J Support, Ultram Experience
Centocor will have the support and experience of J&J's pain product marketing for the expansion of Remicade into the rheumatoid arthritis market.